MCID: VRR004
MIFTS: 49

Verrucous Carcinoma

Categories: Cancer diseases, Oral diseases

Aliases & Classifications for Verrucous Carcinoma

MalaCards integrated aliases for Verrucous Carcinoma:

Name: Verrucous Carcinoma 12 15 17
Verrucous Squamous Cell Carcinoma 12
Verrucous Squamous Carcinoma 12
Carcinoma, Verrucous 43
Carcinoma Verrucous 54
Warty Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3737
MeSH 43 D018289
NCIt 49 C3781
SNOMED-CT 67 89906000
UMLS 71 C0206706

Summaries for Verrucous Carcinoma

Disease Ontology : 12 A squamous cell carcinoma that is a diffuse, papillary, non metastasizing, well differentiated, malignant neoplasm of epidermis or oral epithelium.

MalaCards based summary : Verrucous Carcinoma, also known as verrucous squamous cell carcinoma, is related to esophagus verrucous carcinoma and squamous cell papilloma. An important gene associated with Verrucous Carcinoma is MSN (Moesin), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Clotrimazole and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include cervix, skin and lung, and related phenotypes are cellular and immune system

Wikipedia : 74 Verrucous carcinoma (VC) is an uncommon variant of squamous cell carcinoma. This form of cancer is often... more...

Related Diseases for Verrucous Carcinoma

Diseases related to Verrucous Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 457)
# Related Disease Score Top Affiliating Genes
1 esophagus verrucous carcinoma 33.8 TP53 MDM2 EGFR CDKN2A CCND1
2 squamous cell papilloma 31.6 TP53 CDKN2A
3 penile benign neoplasm 30.8 TP53 CDKN2A
4 vulvar intraepithelial neoplasia 30.8 TP53 CDKN2A
5 oral leukoplakia 30.7 TP53 CDKN2A
6 suppressor of tumorigenicity 3 30.6 TP53 CDKN2A
7 familial retinoblastoma 30.6 TP53 MDM2 CDKN2A
8 actinic cheilitis 30.5 TP53 MDM2
9 anus cancer 30.4 TP53 EGFR CDKN2A
10 basaloid squamous cell carcinoma 30.4 TP53 EGFR CDKN2A
11 esophagitis 30.4 TP53 EGFR CDKN2A
12 malignant peritoneal mesothelioma 30.4 EGFR CDKN2A
13 anal squamous cell carcinoma 30.3 TP53 MDM2 CDKN2A
14 squamous cell carcinoma 30.3 TP53 PTEN MMP9 EGFR CDKN2A CCND1
15 eccrine acrospiroma 30.3 KRT5 KRT10
16 keratoacanthoma 30.2 TP53 KRT10 EGFR
17 cheilitis 30.2 TP53 MMP9 MDM2
18 papilloma 30.2 TP53 PTEN KRT5 KRT10 EGFR CDKN2A
19 gastric squamous cell carcinoma 30.1 KRT5 KRT10
20 serous cystadenocarcinoma 30.1 TYMP TP53 PTEN CDKN2A
21 keratosis, seborrheic 30.0 TP53 KRT5 KRT10 CDKN2A
22 keratinizing squamous cell carcinoma 30.0 TP53 KRT5 EGFR CDKN2A
23 in situ carcinoma 30.0 TP53 PTEN KRT5 EGFR CDKN2A CCND1
24 vulva cancer 30.0 TP53 EGFR CDKN2A CCND1
25 cowden syndrome 1 30.0 TP53 PTEN EGFR
26 endometrial squamous cell carcinoma 29.9 TP53 CDKN2A CDK6
27 adenosquamous carcinoma 29.9 TP53 PTEN KRT5 EGFR
28 barrett esophagus 29.9 TP53 EGFR CDKN2A CCND1
29 peripheral t-cell lymphoma 29.9 TP53 PTEN CCND1
30 inverted papilloma 29.8 TP53 KRT5 EGFR CDKN2A CCND1
31 colon adenocarcinoma 29.8 TP53 PTEN EGFR CCND1
32 keratosis 29.7 TP53 MMP9 KRT5 KRT10 EGFR CDKN2A
33 papillary squamous carcinoma 29.7 KRT5 ERBB3 EGFR CDKN2A
34 penile cancer 29.7 TP53 PTEN EGFR CDKN2A CCND1
35 endometrial adenocarcinoma 29.7 TP53 PTEN EGFR CDKN2A CCND1
36 laryngeal squamous cell carcinoma 29.7 TP53 PTEN EGFR CDKN2A CCND1
37 retinoblastoma 29.6 TP53 MDM2 CDKN2A CDK6 CCND1
38 meningioma, familial 29.4 TP53 PTEN MSN EGFR CDKN2A CCND1
39 skin carcinoma 29.2 TP53 MIR31 EGFR CDKN2A CCND1
40 oropharynx cancer 29.2 TYMP TP53 KRT5 EGFR CDKN2A CCND1
41 lymphoma 29.2 TP53 MDM2 EGFR CDKN2A CDK6 CCND1
42 oral cancer 29.2 TP53 MMP9 MIR31 EGFR CDKN2A CCND1
43 esophageal disease 28.9 TP53 MIR31 MIR125A EGFR CCND1
44 oral squamous cell carcinoma 28.9 TP53 PTEN MMP9 MIR31 MIR195 EGFR
45 skin disease 28.7 TP53 MIR31 MIR125A KRT5 KRT10
46 basal cell carcinoma 28.5 TP53 PTEN MMP9 KRT5 KRT10 EGFR
47 larynx cancer 28.4 TP53 MIR31 MIR195 MIR125A EGFR CDKN2A
48 adenocarcinoma 28.0 TYMP TP53 PTEN MMP9 MDM2 ERBB3
49 renal cell carcinoma, nonpapillary 26.9 TYMP TP53 PTEN MMP9 MIR31 MIR195
50 esophageal cancer 26.8 TYMP TP53 PTEN MMP9 MIR31 MDM2

Graphical network of the top 20 diseases related to Verrucous Carcinoma:



Diseases related to Verrucous Carcinoma

Symptoms & Phenotypes for Verrucous Carcinoma

MGI Mouse Phenotypes related to Verrucous Carcinoma:

45 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.33 CCND1 CDK6 CDKN2A EGFR ERBB3 LRIG1
2 immune system MP:0005387 10.27 CCND1 CDK6 CDKN2A EGFR ERBB3 LRIG1
3 growth/size/body region MP:0005378 10.25 CCND1 CDK6 CDKN2A EGFR ERBB3 KRT5
4 digestive/alimentary MP:0005381 10.24 CCND1 CDKN2A EGFR ERBB3 KRT5 LRIG1
5 cardiovascular system MP:0005385 10.21 CCND1 CDK6 CDKN2A EGFR ERBB3 MDM2
6 endocrine/exocrine gland MP:0005379 10.18 CCND1 CDK6 CDKN2A EGFR ERBB3 LRIG1
7 integument MP:0010771 10.18 CCND1 CDKN2A EGFR ERBB3 KRT5 LRIG1
8 nervous system MP:0003631 10.11 CCND1 CDK6 CDKN2A EGFR ERBB3 LRIG1
9 neoplasm MP:0002006 10.1 CCND1 CDK6 CDKN2A EGFR ERBB3 LRIG1
10 muscle MP:0005369 10.03 CDK6 CDKN2A EGFR ERBB3 MDM2 MMP9
11 limbs/digits/tail MP:0005371 10 EGFR KRT5 LRIG1 MDM2 MMP9 PTEN
12 normal MP:0002873 9.92 CCND1 EGFR ERBB3 LRIG1 MDM2 MSN
13 respiratory system MP:0005388 9.76 CCND1 CDKN2A EGFR ERBB3 MMP9 MSN
14 pigmentation MP:0001186 9.73 CDKN2A EGFR ERBB3 MDM2 PTEN TP53
15 skeleton MP:0005390 9.61 CCND1 CDKN2A EGFR LRIG1 MDM2 MMP9
16 vision/eye MP:0005391 9.23 CCND1 CDK6 CDKN2A EGFR LRIG1 MMP9

Drugs & Therapeutics for Verrucous Carcinoma

Drugs for Verrucous Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 180)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clotrimazole Approved, Vet_approved Phase 2, Phase 3 23593-75-1 2812
2
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
3
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
4
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
5
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
6
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
7
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
8
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
9
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
10
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
11
Panitumumab Approved, Investigational Phase 3 339177-26-3 50070211
12
Promethazine Approved, Investigational Phase 3 60-87-7 4927
13
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
14
Histamine Approved, Investigational Phase 3 51-45-6 774
15
Diphenhydramine Approved, Investigational Phase 3 58-73-1, 147-24-0 3100
16
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
17
Fluorouracil Approved Phase 3 51-21-8 3385
18
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
19 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
20 Liver Extracts Phase 3
21 Cola Phase 3
22 Antidotes Phase 3
23 Anti-Bacterial Agents Phase 3
24 Antifungal Agents Phase 2, Phase 3
25 Antibiotics, Antitubercular Phase 3
26 Neurotransmitter Agents Phase 3
27 Muscarinic Agonists Phase 3
28 Cholinergic Agents Phase 3
29 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
30 Hormone Antagonists Phase 2, Phase 3
31 Central Nervous System Stimulants Phase 3
32 Contraceptives, Oral Phase 3
33 Antineoplastic Agents, Hormonal Phase 3
34 Contraceptive Agents Phase 3
35
Megestrol Phase 3 3562-63-8 19090 3080587
36 Vitamins Phase 3
37 Calcium, Dietary Phase 3
38 Antidepressive Agents Phase 3
39 Hypnotics and Sedatives Phase 3
40 Histamine Antagonists Phase 3
41 Psychotropic Drugs Phase 3
42
Histamine Phosphate Phase 3 51-74-1 65513
43 Antidepressive Agents, Tricyclic Phase 3
44 Anesthetics Phase 3
45 Narcotics Phase 3
46 Analgesics Phase 3
47 Analgesics, Opioid Phase 3
48 Anesthetics, General Phase 3
49 Anesthetics, Intravenous Phase 3
50 Immunoglobulins Phase 3

Interventional clinical trials:

(show top 50) (show all 141)
# Name Status NCT ID Phase Drugs
1 A Multi-centre Randomised Phase III Trial Comparing PET-CT Guided Watch and Wait Policy Versus Planned Neck Dissection for the Management of Locally Advanced (N2/N3) Nodal Metastases in Patients With Head and Neck Squamous Cancer Unknown status NCT00720070 Phase 3
2 Role of Peri-operative Immunonutrition in Cancers of the Higher Aero-digestive Tract Completed NCT00765440 Phase 3
3 A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Cevimeline in the Treatment of Xerostomia Secondary to Radiation Therapy for Cancer in the Head and Neck Region Completed NCT00017511 Phase 3 cevimeline hydrochloride
4 A PHASE II/III PILOT STUDY OF THE EFFECTS OF PROPHYLACTIC FLUCONAZOLE THERAPY ON MUCOSITIS IN PATIENTS UNDERGOING RADIATION TREATMENT FOR HEAD AND NECK CANCER Completed NCT00002533 Phase 2, Phase 3 fluconazole
5 A Phase III, Double-Blind, Randomized Study Of The Effect Of Megestrol Acetate On Weight And Health Related Quality Of Life In Head And Neck Cancer Patients Receiving Radiation Therapy Completed NCT00006799 Phase 3 megestrol acetate
6 Acupuncture for Pain and Dysfunction Following Neck Dissection: A Randomized, Controlled, Phase III Trial Completed NCT00090337 Phase 3
7 Phase III Randomized Study of Radiotherapy Alone vs With Concurrent Chemotherapy With MTX or VBMF (VCR/BLEO/MTX/5-FU) vs Subsequent Chemotherapy vs Concurrent and Subsequent Chemotherapy in Patients With Advanced Head and Neck Cancer Completed NCT00002476 Phase 3 fluorouracil;leucovorin calcium;methotrexate;vincristine sulfate
8 A Phase III Study of Standard Fractionation Radiotherapy With Concurrent High-Dose Cisplatin Versus Accelerated Fractionation Radiotherapy With Panitumumab in Patients With Locally Advanced Stage III and IV Squamous Cell Carcinoma of the Head and Neck Completed NCT00820248 Phase 3 cisplatin
9 A Randomized Double-Blind Study of Doxepin Rinse Versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
10 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
11 A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer Active, not recruiting NCT00588770 Phase 3 Carboplatin;Cisplatin;Docetaxel;Fluorouracil
12 Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered With Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck Active, not recruiting NCT01810913 Phase 2, Phase 3 cisplatin;docetaxel
13 A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer Active, not recruiting NCT00956007 Phase 3
14 A Phase III, Randomized, Double-Blind Study of Lactobacillus Brevis CD2 Lozenges Versus Placebo in the Prevention of Acute Oral Mucositis (OM) in Patients With Head and Neck Cancer Receiving Concurrent Radiotherapy and Chemotherapy Withdrawn NCT01545687 Phase 3
15 Phase III Randomized Study of Hypericum Perforatum (St. John's Wort) Combined With Docetaxel in Patients With Unresectable Solid Tumors Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
16 Randomized Placebo- Controlled Pilot Study of ZD6474 as a Chemopreventive Agent for Premalignant Lesions of the Head and Neck Unknown status NCT01414426 Phase 2 vandetanib
17 A Biomarker Driven Pilot Study of the Pan-class I PI3K Inhibitor NVP-BKM120 in Combination With Cetuximab in Patients With Recurrent/Metastatic Head and Neck Cancer Unknown status NCT01816984 Phase 1, Phase 2 PI3K inhibitor BKM120
18 A Phase II Activity And Safety Study Of IntraDose (Cisplatin/Epinephrine Injectable Gel) When Given In Combination With Systematic Chemotherapy Paclitaxel And Carboplatin In The Treatment Of Patients With Squamous Cell Carcinoma Of The Head And Neck At First Relapse Unknown status NCT00022217 Phase 2 carboplatin;cisplatin-e therapeutic implant;paclitaxel
19 A Phase ll Trial of Induction Docetaxel and S-1 Followed by Concomitant Radiotherapy With Low-dose Daily Cisplatin in Locally Advanced Head and Neck Cancer Unknown status NCT00625937 Phase 2 cisplatin;docetaxel;tegafur-gimeracil-oteracil potassium
20 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
21 Phase II Two Arm Trial of the Proteasome Inhibitor, PS-341 (Velcade TM) in Combination With Irinotecan or PS-341 Alone Followed by the Addition of Irinotecan at Time of Progression in Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT00103259 Phase 2 bortezomib;irinotecan hydrochloride
22 A Randomized, Double-Blind Pilot Study of N-Acetylcysteine Mucoadherent Rinse Versus Placebo for Thickened Secretions and Mucositis Secondary to Chemoradiotherapy in the Management of Head and Neck Malignancies Completed NCT02123511 Phase 2 acetylcysteine
23 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
24 A Phase I, and Biologic Correlative Study of Erlotinib, in Combination With Cetuximab and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma Completed NCT00101348 Phase 1, Phase 2 erlotinib hydrochloride
25 A Phase II Study of AZD0530 for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Completed NCT00513435 Phase 2 saracatinib
26 A Phase II Study of Capecitabine and Lapatinib in Squamous Cell Carcinoma of the Head and Neck Completed NCT01044433 Phase 2 lapatinib ditosylate;capecitabine
27 A Phase 2 Trial of GW572016 in Patients With Metastatic and Recurrent Squamous Cell Carcinomas of the Head and Neck Completed NCT00114283 Phase 2 lapatinib ditosylate
28 A Phase II Trial of Preoperative Soy Isoflavone Supplementation and Molecular Markers in the Prevention of Head and Neck Squamous Carcinoma Completed NCT02007200 Phase 2 Soy Isoflavones
29 Phase II Evaluation of BAY 43-9006 (NSC-724772) in Patients With Recurrent or Metastatic Head and Neck Cancer Completed NCT00096512 Phase 2 sorafenib tosylate
30 A Phase 2 Study of SB-715992 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Completed NCT00095628 Phase 2 ispinesib
31 Phase II Clinical Trial of AZD2171 Monotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Patients Completed NCT00458978 Phase 2 Cediranib Maleate
32 Phase II Trial Of Induction Chemotherapy Followed By Attenuated Chemoradiotherapy For Locally Advanced Head And Neck Squamous Cell Carcinoma Associated With Human Papillomavirus (HPV) Completed NCT02048020 Phase 2 paclitaxel;carboplatin
33 Phase II Trial of Carboplatin/Paclitaxel and Cetuximab, Followed by Carboplatin/Paclitaxel/Cetuximab and Erlotinib, With Correlative Studies in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck. Completed NCT01316757 Phase 2 paclitaxel;carboplatin;erlotinib hydrochloride
34 Efficacy and Safety of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal. Phase II Clinical Trial Completed NCT03584308 Phase 2
35 A T1 Translational Multicenter Randomized Phase II Study of Temsirolimus Versus Cetuximab Plus Temsirolimus in Patients With Recurrent / Metastatic Head and Neck Cancer, Who Failed Prior EGFR Based Therapy Completed NCT01256385 Phase 2 Temsirolimus
36 A Randomized Phase II Study of BMS-247550 (NSC #710428) Given Daily x 5 Days Every 3 Weeks or Weekly in Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck Completed NCT00033618 Phase 2 ixabepilone
37 Food-Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer Completed NCT01469429 Phase 1, Phase 2 chemoprevention;chemoprevention
38 A Phase 2 Study of Dasatinib in Head and Neck Squamous Cell Carcinoma Completed NCT00507767 Phase 2 dasatinib
39 Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab in Patients With Refractory, Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT00939627 Phase 2 sorafenib tosylate
40 Re-irradiation and Stereotactic Cetuximab in Patients With Recurrent Carcinoma of the Head and Neck Completed NCT00738868 Phase 2
41 Treatment of Relapsed or Metastatic Head and Neck Carcinomas With Oxaliplatin and Capecitabine Completed NCT00448552 Phase 2 capecitabine;oxaliplatin
42 A Phase I Study of Concomitant Chemoradiotherapy With 776C85, 5-FU and Hydroxyurea for Patients With Poor Prognosis Oral Cancer Completed NCT00004901 Phase 1, Phase 2 ethynyluracil;fluorouracil;hydroxyurea
43 Phase II Trial of Irinotecan Plus Cisplatin in Patients With Recurrent or Metastatic Squamous Carcinoma of the Head and Neck Completed NCT00639769 Phase 2 cisplatin;irinotecan hydrochloride
44 A Phase II Study of Gemcitabine in Combination With Doxorubicin for Patients With Head and Neck Cancer Completed NCT00509665 Phase 2 doxorubicin hydrochloride;gemcitabine hydrochloride
45 High Dose Ifosfamide, Carboplatin and Etoposide With Amifostine Chemoprotection Completed NCT00003657 Phase 2 Amifostine;Carboplatin;Etoposide;Ifosfamide
46 A Study of Population Pharmacokinetics of Docetaxel (Taxotere) in Caucasian and African-American Cancer Patients Completed NCT00003565 Phase 2 docetaxel
47 A Phase I/IIA Dose-Escalating Trial of BCL-2 Antisense (G3139) Treatment for Patients With Androgen-Independent Prostate Cancer or Other Advanced Solid Tumor Malignancies Completed NCT00003103 Phase 1, Phase 2 docetaxel
48 A Phase I/II Trial of Epirubicin, Carboplatin & Capecitabine in Adult Cancer Patients Completed NCT00021047 Phase 1, Phase 2 capecitabine;carboplatin;epirubicin hydrochloride
49 Vaccine Therapy With Tumor Specific Mutated Ras Peptides and IL-2 or GM-CSF for Adult Patients With Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
50 A Phase II Study of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib, in Combination With Docetaxel and Radiation in Locally Advanced Squamous Cell Cancer of the Head and Neck Completed NCT00720304 Phase 2 docetaxel;erlotinib hydrochloride

Search NIH Clinical Center for Verrucous Carcinoma

Cochrane evidence based reviews: carcinoma, verrucous

Genetic Tests for Verrucous Carcinoma

Anatomical Context for Verrucous Carcinoma

MalaCards organs/tissues related to Verrucous Carcinoma:

40
Cervix, Skin, Lung, Bone, Brain, Lymph Node, Liver

Publications for Verrucous Carcinoma

Articles related to Verrucous Carcinoma:

(show top 50) (show all 1215)
# Title Authors PMID Year
1
Shifts in cellular localization of moesin in normal oral epithelium, oral epithelial dysplasia, verrucous carcinoma and oral squamous cell carcinoma. 54 61
12787041 2003
2
Expression of moesin and its associated molecule CD44 in epithelial skin tumors. 61 54
9696288 1998
3
Characteristics of penile cancer in Japan: An analysis of nationwide hospital-based cancer registry data. 61
32307745 2020
4
Differentiated exophytic vulvar intraepithelial lesion: Clinicopathologic and molecular analysis documenting its relationship with verrucous carcinoma of the vulva. 61
32427961 2020
5
Verrucous hyperplasia and verrucous carcinoma in head and neck: use and benefit of methotrexate. 61
32279645 2020
6
Verrucous carcinoma of the upper lip: An exuberant presentation in a patient with other synchronous lesions. 61
31274469 2020
7
Complex microsurgical perineal reconstruction after resection of a giant verrucous carcinoma associated with anal fistulas in Crohn's disease-a unique case report. 61
32179992 2020
8
Nucleolar organizer regions in human oral verrucous carcinoma and adjacent lining epithelium. 61
32124655 2020
9
Inter-observer Variability in the Diagnosis of Proliferative Verrucous Leukoplakia: Clinical Implications for Oral and Maxillofacial Surgeon Understanding: A Collaborative Pilot Study. 61
30972634 2020
10
Histopathological determinants of autofluorescence patterns in oral carcinoma. 61
32045089 2020
11
Verrucous carcinoma of the esophagus: a case report and literature review. 61
32030515 2020
12
Verrucous Carcinoma in a Giant Cutaneous Horn: A Case Report and Literature Review. 61
32082671 2020
13
Head and neck verrucous carcinoma: A population-based analysis of incidence, treatment, and prognosis. 61
31914052 2020
14
Epithelial-myoepithelial carcinoma on lower lip and microinvasive verrucous carcinoma in vocal cord: Case report. 61
32259043 2020
15
Syringocystadenoma papilliferum associated with verrucous carcinoma of the skin in the same lesion: Report of four cases. 61
31449665 2020
16
A Case Report of an Early Response to Definitive Chemoradiation for Esophageal Carcinoma Cuniculatum. 61
32373377 2020
17
Histopathological Assessment for Esophageal Squamous Cell Carcinoma. 61
32056166 2020
18
Lichenoid Characteristics in Premalignant Verrucous Lesions and Verrucous Carcinoma of the Oral Cavity. 61
30671763 2019
19
[Oral Floor Reconstruction with Digastric Muscle Bipedicle Flap for Advanced Tongue Cancer in Very Elderly Patients-Report of Two Cases]. 61
32156873 2019
20
Clinicopathologic analysis of verrucous hyperplasia, verrucous carcinoma and squamous cell carcinoma as part of the clinicopathologic spectrum of oral proliferative verrucous leukoplakia: A literature review and analysis. 61
31630872 2019
21
Expanded Expression of Toll-Like Receptor 2 in Proliferative Verrucous Leukoplakia. 61
30888638 2019
22
Nonhealing Wounds with Verrucous Presentation in the Neuropathic Patient: A Report of Two Cases. 61
31755775 2019
23
Verrucous Carcinoma of the Nail Bed: A New Case. 61
31799266 2019
24
Mandible extensive intra osseous destructive lesion, a diagnostic challenge. 61
31610243 2019
25
Exophytic verrucous hyperplasia in oral submucous fibrosis: A single-center study. 61
31942120 2019
26
Is primary radiotherapy an acceptable treatment modality for verrucous carcinoma of the larynx? 61
30950508 2019
27
Unusually early-onset plantar verrucous carcinoma. 61
31603976 2019
28
Verrucous psoriasis: A rare variant of psoriasis masquerading as verrucous carcinoma. 61
31440568 2019
29
Verrucous carcinoma on the foot arising in a chronic neuropathic ulcer of leprosy. 61
30841011 2019
30
A Case of Oral Florid Papillomatosis (Verrucous Carcinoma) With Lack of Evidence for Human Papillomavirus Involvement. 61
31335422 2019
31
Verruciform and Condyloma-like Squamous Proliferations in the Anogenital Region. 61
30203987 2019
32
A Novel Surface Enhanced Raman Catheter for Rapid Detection, Classification, and Grading of Oral Cancer. 61
31081261 2019
33
A first case of primary gastric verrucous carcinoma with isolated squamous epithelium in the stomach. 61
30761414 2019
34
Verrucous Carcinoma Arising in Association With Giant Condyloma. 61
30185090 2019
35
Experience with endoscopic resection of oesophageal verrucous carcinoma and literature review. 61
31229974 2019
36
Diagnostic utility of microsurgical carbon dioxide laser excision of oral potentially malignant lesions vs incisional biopsy: a retrospective histopathological review. 61
30948343 2019
37
Verrucous carcinoma: A clinicopathological study. 61
31516246 2019
38
Acral Verrucous Carcinoma. 61
31624653 2019
39
Verrucous carcinoma arising in a long standing Buschke-Löwenstein tumor. 61
30997098 2019
40
Verrucous Carcinoma of the Vulva: A Case Report and Literature Review. 61
31002657 2019
41
Verrucous carcinoma: An unexpected finding arising from a burn scar. 61
30809566 2019
42
HPV-Related Papillary Lesions of the Oral Mucosa: A Review. 61
30693456 2019
43
Human papillomavirus infection is not involved in esophageal verrucous carcinoma. 61
30423307 2019
44
Risk Assessment of Smokeless Tobacco among Oral Precancer and Cancer Patients in Eastern Developmental Region of Nepal 61
30803200 2019
45
[Experience of diagnosis and treatment for 89 patients with Marjolin's ulcers in lower limbs]. 61
30837387 2019
46
Anogenital Verrucous Carcinoma-A case report. 61
30508696 2019
47
Downregulation of Notch4 - a prognostic marker in distinguishing oral verrucous carcinoma from oral squamous cell carcinoma. 61
29162408 2019
48
Is Syringocystadenoma Papilliferum Incidental in This Verrucous Carcinoma? 61
31772805 2019
49
Non-urothelial carcinomas of the bladder. 61
30565306 2019
50
Case study of verrucous carcinoma of the hand: rare location. 61
31489071 2019

Variations for Verrucous Carcinoma

Expression for Verrucous Carcinoma

Search GEO for disease gene expression data for Verrucous Carcinoma.

Pathways for Verrucous Carcinoma

Pathways related to Verrucous Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.81 TYMP TP53 PTEN MDM2 ERBB3 EGFR
2
Show member pathways
13.69 TYMP TP53 MMP9 MDM2 ERBB3 EGFR
3
Show member pathways
13.4 TYMP TP53 PTEN MDM2 ERBB3 EGFR
4
Show member pathways
12.95 TP53 PTEN MDM2 ERBB3 EGFR CDK6
5
Show member pathways
12.94 TP53 MDM2 EGFR CDKN2A CDK6 CCND1
6
Show member pathways
12.81 TP53 MSN MDM2 CDK6 CCND1
7
Show member pathways
12.78 TP53 PTEN MMP9 MDM2 EGFR CDKN2A
8
Show member pathways
12.75 TP53 PTEN EGFR CDKN2A CDK6 CCND1
9
Show member pathways
12.73 TP53 PTEN MDM2 ERBB3 EGFR
10 12.73 TP53 PTEN MMP9 MDM2 EGFR CDKN2A
11
Show member pathways
12.59 TP53 PTEN MDM2 ERBB3 EGFR CCND1
12
Show member pathways
12.58 TP53 MDM2 CDKN2A CDK6 CCND1
13 12.52 TP53 MDM2 CDKN2A CDK6 CCND1
14
Show member pathways
12.51 TP53 PTEN MMP9 MDM2 ERBB3 EGFR
15
Show member pathways
12.49 TP53 PTEN ERBB3 EGFR
16
Show member pathways
12.49 TP53 PTEN MDM2 EGFR
17
Show member pathways
12.44 TP53 MDM2 ERBB3 EGFR
18
Show member pathways
12.4 TP53 PTEN MDM2 CCND1
19
Show member pathways
12.35 TP53 CDKN2A CDK6 CCND1
20 12.35 TP53 MDM2 CDKN2A CDK6 CCND1
21 12.34 TP53 PTEN CDKN2A CCND1
22
Show member pathways
12.33 TP53 PTEN MDM2 CDKN2A CDK6 CCND1
23
Show member pathways
12.3 TP53 PTEN MDM2 EGFR CCND1
24 12.28 TP53 MDM2 CDKN2A CDK6 CCND1
25
Show member pathways
12.26 TP53 PTEN MDM2 CCND1
26
Show member pathways
12.2 TP53 PTEN MDM2 ERBB3 EGFR CCND1
27 12.19 TP53 MMP9 EGFR CCND1
28 12.18 TP53 MSN MMP9 MDM2 ERBB3 EGFR
29 12.11 TP53 PTEN MDM2 EGFR CCND1
30
Show member pathways
12.1 PTEN MDM2 EGFR CCND1
31 12.08 TP53 PTEN MDM2 EGFR
32 12.04 TP53 PTEN MDM2 CDKN2A CDK6 CCND1
33 12.02 TP53 MMP9 EGFR CCND1
34
Show member pathways
11.97 MDM2 LRIG1 ERBB3 EGFR
35 11.96 TP53 PTEN MDM2 CDKN2A
36 11.95 TP53 PTEN MDM2 CDKN2A CCND1
37 11.89 TP53 PTEN MMP9 MIR31 MIR195 MIR125A
38 11.88 TP53 PTEN CDK6 CCND1
39 11.87 PTEN MDM2 EGFR CCND1
40 11.84 TP53 MDM2 CDK6 CCND1
41 11.81 TP53 MDM2 KRT5
42
Show member pathways
11.75 TP53 MDM2 CDKN2A
43 11.75 TP53 MDM2 CDKN2A
44 11.75 TP53 PTEN MDM2 EGFR CDKN2A CDK6
45 11.72 TP53 PTEN EGFR
46 11.69 MSN MMP9 EGFR
47 11.65 MSN MMP9 EGFR
48 11.6 TP53 MDM2 CDKN2A
49 11.58 TP53 PTEN MDM2 CCND1
50 11.55 TP53 CDK6 CCND1

GO Terms for Verrucous Carcinoma

Cellular components related to Verrucous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.23 MSN MMP9 MIR31 MIR125A LRIG1 KRT10

Biological processes related to Verrucous Carcinoma according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.97 PTEN MDM2 ERBB3 EGFR CCND1
2 negative regulation of apoptotic process GO:0043066 9.96 TP53 PTEN MMP9 MDM2 EGFR
3 response to drug GO:0042493 9.92 TP53 PTEN MDM2 CCND1
4 heart development GO:0007507 9.85 TP53 PTEN MDM2 ERBB3
5 negative regulation of cell proliferation GO:0008285 9.85 TP53 PTEN MIR195 CDKN2A CDK6
6 positive regulation of apoptotic process GO:0043065 9.83 TP53 PTEN MMP9 MIR195 CDKN2A
7 regulation of cell proliferation GO:0042127 9.81 TP53 ERBB3 EGFR CDK6
8 G1/S transition of mitotic cell cycle GO:0000082 9.78 CDKN2A CDK6 CCND1
9 regulation of cell cycle GO:0051726 9.71 TP53 PTEN CDK6 CCND1
10 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.67 PTEN CDKN2A CDK6
11 hematopoietic stem cell differentiation GO:0060218 9.62 TP53 CDK6
12 cardiac septum morphogenesis GO:0060411 9.61 TP53 MDM2
13 replicative senescence GO:0090399 9.6 TP53 CDKN2A
14 response to magnesium ion GO:0032026 9.59 MDM2 CCND1
15 amyloid fibril formation GO:1990000 9.58 MDM2 CDKN2A
16 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.58 TP53 EGFR
17 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.54 MIR31 MIR125A
18 negative regulation of mitotic cell cycle GO:0045930 9.54 TP53 MIR195 EGFR
19 mitotic G1 DNA damage checkpoint GO:0031571 9.52 TP53 CCND1
20 cellular response to UV-C GO:0071494 9.48 TP53 MDM2
21 regulation of cell motility GO:2000145 9.33 ERBB3 EGFR CDK6
22 cellular response to actinomycin D GO:0072717 9.32 TP53 MDM2
23 response to UV-A GO:0070141 9.26 EGFR CCND1
24 positive regulation of gene expression GO:0010628 9.23 TP53 PTEN MSN MIR125A MDM2 ERBB3
25 positive regulation of cardiac muscle cell apoptotic process GO:0010666 9.13 TP53 PTEN MIR195

Molecular functions related to Verrucous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ubiquitin protein ligase binding GO:0031625 9.56 TP53 MDM2 ERBB3 EGFR
2 protein kinase binding GO:0019901 9.43 TP53 PTEN MSN EGFR CDKN2A CCND1
3 disordered domain specific binding GO:0097718 9.33 TP53 MDM2 CDKN2A
4 enzyme binding GO:0019899 9.1 TP53 PTEN MSN MDM2 EGFR CCND1

Sources for Verrucous Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....